Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquilin-like protein (**UBQLNL**) is a member of the *ubiquilin* family, which is characterized by the presence of a ubiquitin-like (UBL) domain at the N-terminus and a ubiquitin-associated (UBA) domain at the C-terminus, with an intrinsically disordered and variable central region[1][2][3]. While UBQLN1, UBQLN2, UBQLN3, and UBQLN4 are well-studied and broadly implicated in protein quality control and proteostasis—acting as shuttle factors to deliver ubiquitinated substrates to the proteasome[1][2][3]—**UBQLNL** appears to be a less-characterized or even species/annotation-specific family member. Very limited data are available for UBQLNL itself, and standard references to therapeutic target activity, biological function, disease relevance, or clinically validated druggability are unavailable. The UBQLNL protein is provisionally annotated and does not have established roles similar to UBQLN1/2/4, nor has it been described as a validated or emerging therapeutic target. Most information regarding protein quality control functions in this family is attributable to other ubiquilin (UBQLN) proteins; by convention and based on available sources, **UBQLNL** is not considered a canonical drug target or receptor. Clarification and Key Limitations: - Available scientific literature and reviews focus on UBQLN1, UBQLN2, and UBQLN4, with UBQLNL not addressed as a functional molecule in those contexts[1][2][3]. - UBQLNL mapping and annotation are primarily from gene-centric sources and large-scale datasets, without confirmatory experimental evidence of function or disease role. - Alternate names and database aliases (MGC20470, MGC26958) further indicate a lack of strong curation and limited biological validation. Conclusion: UBQLNL (Ubiquilin-like protein) is a presumed member of the ubiquilin protein family with no well-defined biological function, disease relevance, or established therapeutic target status. The entered target should be considered an **incorrect or insufficiently validated entry** for structured target curation. All established biological functions and disease links from the ubiquilin family should not be indiscriminately assigned to UBQLNL without specific evidence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquilin-like protein (UBQLNL).